Sugi Predict

Sugi Predict / Compounds / SCHEMBL907263

SCHEMBL907263

SCHEMBL907263

Cc1ccc(S(=O)(=O)CC(CS(=O)(=O)c2ccc(C)cc2)C(=O)c2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.55
▸ CA1 P00915 1/20 0.55
▸ CA2 P00918 1/20 0.55
▸ CA9 Q16790 1/20 0.55
▸ ALDH1A1 P00352 4/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ TDP1 Q9NUW8 2/20 0.48
▸ RECQL P46063 1/20 0.48
▸ HSD11B1 P28845 1/20 0.48
▸ SRD5A2 P31213 2/20 0.47
▸ TAS2R14 Q9NYV8 2/20 0.47
▸ TSHR P16473 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ STAT3 P40763 1/20 0.46
▸ MAPT P10636 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ KMT2A Q03164 3/20 0.43
▸ PAX8 Q06710 1/20 0.43
▸ LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12642017 0.94 ALDH1A1 (0.50) CA12CA1CA2CA9ALDH1A1
SCHEMBL28667122 0.90 CA12 (0.46) CA12CA1CA2CA9ALDH1A1
SCHEMBL29211809 0.89 CA12 (0.45) CA12CA1CA2CA9ALDH1A1
SCHEMBL17401074 0.88 TDP1 (0.47) CA12CA1CA2CA9ALDH1A1
SCHEMBL21151897 0.88 ALDH1A1 (0.45) CA12CA1CA2CA9ALDH1A1
SCHEMBL13333146 0.88 MAPT (0.50) ALDH1A1SMN1; SMN2TDP1RECQLHSD11B1
SCHEMBL17688654 0.88 ALDH1A1 (0.48) CA12CA1CA2CA9ALDH1A1
SCHEMBL30831293 0.88 TSHR (0.56) CA12CA1CA2CA9ALDH1A1
SCHEMBL23280908 0.87 ALDH1A1 (0.44) CA12CA1CA2CA9ALDH1A1
SCHEMBL907548 0.87 ALDH1A1 (0.51) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250302984-A1 Antibody-Drug Conjugates Against EPH Receptor A5 (Epha5) for Treatment of Carcinoma MBRACE THERAPEUTICS, INC. (US) 2025-10-02 — — US disclosed
US-20250255980-A1 Antibody-Drug Conjugates Against the Glucose-regulating Protein 78 (GRP78) MBRACE THERAPEUTICS INC (US) 2025-08-14 — — US disclosed
WO-2025082283-A1 LIGAND COMPOUND OF CYCLOPEPTIDE STRUCTURE, NUCLIDE MARKER THEREOF, PHARMACEUTICAL COMPOSITION, AND USE 四川科伦博泰生物医药股份有限公司 2025-04-24 — — WO disclosed
US-20240293549-A1 Conjugates And Conjugating Reagents POLYTHERICS LIMITED (GB) 2024-09-05 — — US disclosed
US-20240201178-A1 DETECTION ASSAY RANDOX LABORATORIES LTD (GB) 2024-06-20 — — US disclosed
EP-4314822-A1 DETECTION ASSAY Randox Laboratories Ltd. (GB) 2024-02-07 — — EP disclosed
EP-4314821-A1 CORONAVIRUS ASSAY Randox Laboratories Ltd. (GB) 2024-02-07 — — EP disclosed
US-11865183-B2 Conjugates and conjugating reagents comprising a linker that includes at least two (−CH2—CH2—O—) units in a ring POLYTHERICS LIMITED (GB) 2024-01-09 — — US disclosed
EP-4282434-A2 ANTIBODIES, USES THEREOF AND CONJUGATES THEREOF Abzena (UK) Limited (GB) 2023-11-29 — — EP disclosed
US-20230357313-A1 SERUM RESISTANT BIS-SULFHYDRYL SPECIFIC BIOTINYLATION REAGENT Miltenyi Biotec B.V. & Co. KG (DE) 2023-11-09 — — US disclosed
EP-1893741-A1 CELL-BASED MICROARRAYS, AND METHODS FOR THEIR PREPARATION AND USE Beckman Coulter, Inc. (US) 2008-03-05 — — EP disclosed
WO-2007001817-A1 CELL-BASED MICROARRAYS, AND METHODS FOR THEIR PREPARATION AND USE BECKMAN COULTER, INC. (US) 2007-01-04 — — WO disclosed
US-20060292559-A1 Cell-based microarrays, and methods for their preparation and use BECKMAN COULTER, INC. (US) 2006-12-28 — — US disclosed
US-20060210526-A1 polyoxyethylene glycol-protein conjugate linked via linking group ABZENA (CAMBRIDGE) LIMITED (GB) 2006-09-21 — — US disclosed
EP-1648518-A2 CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION Polytherics Limited (GB) 2006-04-26 — — EP disclosed
WO-2005007197-A2 CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION POLYTHERICS LIMITED (GB) 2005-01-27 — — WO disclosed
EP-0779934-B1 COMPOSITIONS AND METHODS FOR USE IN DETECTION OF ANALYTES BECKMAN COULTER INC (US) 2000-04-05 — — EP disclosed
US-5648213-A IMMUNOASSAY BECKMAN INSTRUMENTS, INC. (US) 1997-07-15 — — US disclosed
EP-0779934-A1 COMPOSITIONS AND METHODS FOR USE IN DETECTION OF ANALYTES BECKMAN INSTRUMENTS, INC. (US) 1997-06-25 — — EP disclosed
WO-1996006948-A1 COMPOSITIONS AND METHODS FOR USE IN DETECTION OF ANALYTES BECKMAN INSTRUMENTS, INC. (US) 1996-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240293549-A1 Conjugates And Conjugating Reagents ANPEP, NGLY1, PCTP CA12 1346/4885CA1 2872/4885CA2 4634/4885
US-20230357313-A1 SERUM RESISTANT BIS-SULFHYDRYL SPECIFIC BIOTINYLATION REAGENT BTD, HLCS, CBS CA12 3219/4885CA1 4471/4885CA2 3796/4885
US-20250255980-A1 Antibody-Drug Conjugates Against the Glucose-regulating Protein 78 (GRP78) HSPA8, HSPA5, HSPA2 CA12 1113/4885CA1 2706/4885CA2 3022/4885
US-20250302984-A1 Antibody-Drug Conjugates Against EPH Receptor A5 (Epha5) for Treatment of Carcinoma EPHA5, EPHA3, EPHA2 CA12 698/4885CA1 1367/4885CA2 3564/4885
US-20060210526-A1 polyoxyethylene glycol-protein conjugate linked via linking group F13A1, F13B, SSB CA12 1596/4885CA1 2641/4885CA2 4461/4885
US-11865183-B2 Conjugates and conjugating reagents comprising a linker that includes at least two (−CH2—CH2—O—) units in a ring BCR, CD2BP2, LANCL2 CA12 567/4885CA1 1626/4885CA2 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.